2024
Association Between Immunoparesis and Treatment Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
Siwakoti A, Khadka S, Grimshaw A, Giri S. Association Between Immunoparesis and Treatment Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e870-e877. PMID: 39179448, DOI: 10.1016/j.clml.2024.07.008.Peer-Reviewed Original ResearchNewly diagnosed multiple myelomaProgression free survivalImpact of immunoparesisVisual examination of funnel plotsAssociated with worse OSOverall survivalMultiple myelomaFree survivalPrognostic impactPre-published protocolFunnel plotMeta-analysisHazard ratioTreatment outcomes of patientsPublication biasOutcomes of patientsContour-enhanced funnel plotsImmune system perturbationsInfection rateCause of mortalityInfection riskMicro AbstractClinical outcomesImmunoparesisPolyclonal immunoglobulinsLow skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta‐analysis
Anabtawi N, Pasala M, Grimshaw A, Kharel P, Bal S, Godby K, Siwakoti A, Buford T, Bhatia S, Costa L, Williams G, Giri S. Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta‐analysis. Journal Of Cachexia Sarcopenia And Muscle 2024, 15: 1084-1093. PMID: 38558541, PMCID: PMC11154774, DOI: 10.1002/jcsm.13446.Peer-Reviewed Original ResearchConceptsLow skeletal muscle massNon-relapse mortalityProgression free survivalTreatment-related toxicityHaematological malignanciesOverall survivalSkeletal muscle massMuscle massEffects of low skeletal muscle massImpact of low skeletal muscle massIncreased risk of treatment-related toxicityPresence of low skeletal muscle massRisk of treatment-related toxicityHazard ratioAssociated with worse survival outcomesAssociated with worse OSDerSimonian-Laird random-effects modelModerate heterogeneityInferior overall survivalWorse survival outcomesConfidence intervalsRandom-effects modelFree survivalSolid malignanciesPre-published protocol
2022
Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study
Lam R, Tarangelo N, Wang R, Horibe M, Grimshaw AA, Jain D, Haffar S, Bazerbachi F, Kunz PL, Li DK. Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study. The Oncologist 2022, 27: 751-759. PMID: 35589098, PMCID: PMC9438916, DOI: 10.1093/oncolo/oyac093.Peer-Reviewed Original ResearchConceptsGastric signet ring cell carcinomaSignet ring cell carcinomaMicroangiopathic hemolytic anemiaHemolytic anemiaCell carcinomaMultivariable Cox proportional hazards regression modelingCox proportional hazards regression modelingSystematic reviewRare paraneoplastic syndromeStage-matched casesEnd Results (SEER) databaseLate-stage complicationsRisk of mortalityCase-control studyBone painParaneoplastic syndromeFatal complicationMedian survivalMetastatic diseaseOverall survivalLymph nodesIndex presentationPrognostic featuresResults databasePooled cohort
2021
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis
Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 873.e1-873.e13. PMID: 34052505, PMCID: PMC8478722, DOI: 10.1016/j.jtct.2021.05.016.Peer-Reviewed Original ResearchConceptsConditioning regimen intensityAllo-HCTRegimen intensityChronic graftTransplant characteristicsGraft failureOverall survivalPatient ageSubgroup analysisDynamic International Prognostic Scoring System scoresSystematic reviewAllogeneic hematopoietic cell transplantationInternational Prognostic Scoring System scoreCurative therapeutic modalityNon-relapse mortalityTransplant-related mortalityMedian patient ageOutcomes of patientsSecondary graft failureCo-primary outcomesHematopoietic cell transplantHematopoietic cell transplantationRandomized clinical trialsHeterogeneity of patientsRandom-effects model
2019
Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials
Giri S, Aryal M, Yu H, Grimshaw A, Pathak R, Huntington S, Dhakal B. Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials. Blood 2019, 134: 2188. DOI: 10.1182/blood-2019-130389.Peer-Reviewed Original ResearchProgression-free survivalOverall response rateHematopoietic cell transplantFront-line treatmentAdverse eventsOverall survivalMM patientsMultiple myelomaFrontline regimensClinical trialsAdvisory CommitteeCommon grade 3Cumulative ranking (SUCRA) probabilitiesFront-line regimensHigher adverse eventsPrimary efficacy outcomeTransplant-ineligible patientsPhase III RCTsNetwork Meta-AnalysisBias assessment toolRisk of biasEvaluation of efficacyIndividual patient needsEfficacious regimenEfficacious regimens